Overview
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
Basic Stats
The share price of Nurix Therapeutics, Inc. as of September 5, 2025 is $9.90 / share. This is an increase of 6.00% from the prior week. The market cap (or net worth) of Nurix Therapeutics, Inc. as of September 5, 2025 is $756.69 MM.
The Factor Analysis chart (below right) shows a view of Nurix Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 756.69 MM |
| EV | 672.43 MM |
| Shares Out. | 76.43 MM |
| Earnings Date | |
| EPS (TTM) | -2.71 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.31 |
| Short Shares Avail. | 0.30 MM |
| Short Interest | 12.88 MM |
| Short Float | 20.95 % |
| Days to Cover | 20.24 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | -59.49 % |
| Volatility (1 yr) | 0.61 |
| Beta | 1.31 |
| Sharpe Ratio (1 yr) | -1.05 |
| Sortino Ratio (1 yr) | -1.68 |
| PE Ratio | -3.65 |
| Price/Book | 1.69 |
| Price/TBV | 1.69 |
| Book/Market | 0.59 |
| EBIT/EV | -0.31 |
| EBIT(3yr avg)/EV | -0.26 |
| ROA | -0.40 |
| ROE | -0.55 |
| ROIC | -0.42 |
| CROIC | -0.07 |
| OCROIC | -0.43 |
| Implied Volatility | 82.00 % |
| Put/Call OI Ratio | 0.09 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Nurix Therapeutics, Inc. is $30.60. The forecasts range from a low of $16.16 to a high of $43.05. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Nurix Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-13 | SVB Leerink | Outperform | Maintains | |
| 2022-10-11 | Morgan Stanley | Equal-Weight | Initiate | |
| 2022-10-07 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-07-12 | Needham | Buy | Maintains | |
| 2022-07-11 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-07-08 | JP Morgan | Overweight | Maintains | |
| 2022-07-08 | Baird | Outperform | Maintains | |
| 2022-05-31 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2022-05-27 | Needham | Buy | Maintains | |
| 2022-04-18 | RBC Capital | Outperform | Maintains | |
| 2022-04-14 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-04-11 | Wells Fargo | Equal-Weight | Maintains | |
| 2022-02-10 | Wells Fargo | Equal-Weight | Initiate | |
| 2021-12-29 | HC Wainwright & Co. | Buy | Initiate | |
| 2021-10-27 | SVB Leerink | Outperform | Maintains | |
| 2021-10-14 | SVB Leerink | Outperform | Initiate | |
| 2021-04-30 | RBC Capital | Outperform | Initiate | |
| 2021-04-14 | Berenberg | Buy | Initiate | |
| 2021-01-29 | JP Morgan | Overweight | Maintains | |
| 2021-01-08 | Needham | Buy | Maintains | |
| 2020-11-19 | Baird | Outperform | Initiate | |
| 2020-08-18 | Stifel | Buy | Initiate | |
| 2020-08-18 | Piper Sandler | Overweight | Initiate | |
| 2020-08-18 | Needham | Buy | Initiate | |
| 2020-08-18 | JP Morgan | Overweight | Initiate | |
| 2023-02-10 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-10 | RBC Capital | Outperform | Maintains | |
| 2023-02-10 | Needham | Buy | Maintains | |
| 2023-02-13 | JP Morgan | Overweight | Maintains | |
| 2023-02-14 | Stifel | Buy | Maintains | |
| 2023-02-28 | Oppenheimer | Outperform | Initiate | |
| 2023-03-09 | Barclays | Overweight | Initiate | |
| 2023-03-21 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-04-14 | RBC Capital | Outperform | Reiterate | |
| 2023-04-14 | Needham | Buy | Reiterate | |
| 2023-04-21 | Needham | Buy | Reiterate | |
| 2023-04-27 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-11-02 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-07-24 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-07-17 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-09-07 | Needham | Buy | Buy | Reiterate |
| 2024-06-05 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-09-08 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-10-13 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-10-13 | Needham | Buy | Buy | Reiterate |
| 2024-02-16 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-02-16 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-02-16 | Needham | Buy | Buy | Reiterate |
| 2024-04-02 | Needham | Buy | Buy | Maintains |
| 2024-04-11 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-04-10 | Needham | Buy | Buy | Reiterate |
| 2024-02-26 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-04-09 | Needham | Buy | Buy | Reiterate |
| 2024-02-20 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-02-02 | Needham | Buy | Buy | Reiterate |
| 2024-03-11 | Needham | Buy | Buy | Reiterate |
| 2024-04-11 | Baird | Outperform | Outperform | Maintains |
| 2024-04-11 | Needham | Buy | Buy | Reiterate |
| 2024-05-15 | Stifel | Buy | Buy | Maintains |
| 2024-05-14 | Needham | Buy | Buy | Reiterate |
| 2024-05-14 | Stephens & Co. | Overweight | Initiate | |
| 2024-07-12 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-07-12 | Needham | Buy | Buy | Maintains |
| 2024-06-18 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-06-17 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-07-15 | Barclays | Overweight | Overweight | Maintains |
| 2024-07-15 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-06-27 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-06-17 | Needham | Buy | Buy | Reiterate |
| 2024-08-14 | Oppenheimer | Outperform | Outperform | Maintains |
| 2025-04-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-21 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-10-21 | Needham | Buy | Buy | Reiterate |
| 2025-04-29 | Needham | Buy | Buy | Reiterate |
| 2024-09-04 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-10-14 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-10-14 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-14 | Needham | Buy | Buy | Reiterate |
| 2024-11-06 | Needham | Buy | Buy | Reiterate |
| 2024-07-31 | Truist Securities | Buy | Initiate | |
| 2025-01-21 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-02-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-10-11 | Jefferies | Buy | Initiate | |
| 2024-12-10 | Needham | Buy | Buy | Reiterate |
| 2024-12-06 | BMO Capital | Outperform | Initiate | |
| 2024-10-24 | UBS | Buy | Initiate | |
| 2025-01-29 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-01-29 | Stifel | Buy | Buy | Maintains |
| 2025-01-29 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-01-29 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-01-29 | Needham | Buy | Buy | Maintains |
| 2025-03-17 | Leerink Partners | Market Perform | Initiate | |
| 2024-12-10 | BTIG | Buy | Initiate | |
| 2024-12-11 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-04-09 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-04-09 | Needham | Buy | Buy | Maintains |
| 2025-04-09 | Stifel | Buy | Buy | Maintains |
| 2025-07-10 | Oppenheimer | Outperform | Outperform | Maintains |
| 2025-07-10 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-07-31 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2025-07-10 | UBS | Buy | Buy | Maintains |
| 2025-07-14 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-07-15 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
